christinemahler/aie5-midterm

SentenceTransformer based on Snowflake/snowflake-arctic-embed-l

This is a sentence-transformers model finetuned from Snowflake/snowflake-arctic-embed-l. It maps sentences & paragraphs to a 1024-dimensional dense vector space and can be used for semantic textual similarity, semantic search, paraphrase mining, text classification, clustering, and more.

Model Details

Model Description

• Model Type: Sentence Transformer
• Base model: Snowflake/snowflake-arctic-embed-l
• Maximum Sequence Length: 512 tokens
• Output Dimensionality: 1024 dimensions
• Similarity Function: Cosine Similarity

Model Sources

• Documentation: Sentence Transformers Documentation
• Repository: Sentence Transformers on GitHub
• Hugging Face: Sentence Transformers on Hugging Face

Full Model Architecture

SentenceTransformer(
  (0): Transformer({'max_seq_length': 512, 'do_lower_case': False}) with Transformer model: BertModel 
  (1): Pooling({'word_embedding_dimension': 1024, 'pooling_mode_cls_token': True, 'pooling_mode_mean_tokens': False, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False, 'pooling_mode_weightedmean_tokens': False, 'pooling_mode_lasttoken': False, 'include_prompt': True})
  (2): Normalize()
)

Usage

Direct Usage (Sentence Transformers)

First install the Sentence Transformers library:

pip install -U sentence-transformers

Then you can load this model and run inference.

from sentence_transformers import SentenceTransformer

# Download from the 🤗 Hub
model = SentenceTransformer("christinemahler/aie5-midterm")
# Run inference
sentences = [
    'What are the responsibilities of the PD(s)/PI(s) in managing the activities of the approved projects under the cooperative agreement?',
    'RFA-AI-24-079: Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional) Section VI. Award Administration Information\n    \n \n \n \n    1. Award Notices\n    \n \n    A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipient’s business official.\n    \n \n    In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.\n    \n \n    Recipients must comply with any funding restrictions described in\n     \n     Section IV.6. Funding Restrictions\n     \n    . Any pre-award costs incurred before receipt of the NoA are at the applicant\'s own risk. \xa0For more information on the Notice of Award, please refer to the\n     \n     NIH Grants Policy Statement Section 5. The Notice of Award\n     \n    and NIH Grants & Funding website, see\n     \n     Award Process.\n     \n \n \n \n \n    Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.\n    \n \n    ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain “applicable clinical trials” on the ClinicalTrials.gov Protocol Registration and Results System Information Website (\n     \n     https://register.clinicaltrials.gov\n     \n    ). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see\n     \n     https://grants.nih.gov/policy/clinical-trials/reporting/index.htm\n     \n \n \n    Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.\n    \n \n    Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).\n    \n \n    Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).\n    \n \n \n \n    Prior Approval of Pilot Projects\n    \n \n    Recipient-selected projects that involve {clinical trials or studies involving greater than minimal risk to human subjects} require prior approval by NIH prior to initiation.\n    \n \n \n     The recipient institution will comply with the NIH\n      \n      Guidance on Changes That Involve Human Subjects in Active Awards and That Will Require Prior NIH Approval\n      \n     .\n     \n \n     The recipient institution will provide NIH with specific plans for data and safety monitoring, and will notify the IRB and NIH of serious adverse events and unanticipated problems, consistent with\n      \n      NIH DSMP policies\n      \n     .\n     \n \n \n \n \n    2. Administrative and National Policy Requirements\n    \n \n    The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:\n    \n \n \n     The rules listed at\n      \n      2 CFR Part 200\n      \n     , Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards.\n     \n \n     All NIH grant and cooperative agreement awards include the\n      \n      NIH Grants Policy Statement\n      \n     as part of the terms and conditions in the Notice of Award (NoA). The NoA includes the requirements of this NOFO. For these terms of award, see the\n      \n      NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General\n      \n     and\n      \n      Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities\n      \n     .\n     \n \n     If a recipient receives an award, the recipient must follow all applicable nondiscrimination laws. The recipient agrees to this when registering in SAM.gov. The recipient must also submit an Assurance of Compliance (\n      \n      HHS-690\n      \n     ). To learn more, see the\n      \n      Laws and Regulations Enforced by the\xa0HHS Office for Civil Rights website\n      \n     .\n      \n \n       HHS recognizes that NIH research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this NOFO.\n       \n \n \n \n \n    All federal statutes and regulations relevant to federal financial assistance, including those highlighted in\n     \n     NIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.\n     \n \n \n    Recipients are responsible for ensuring that their activities comply with all applicable federal regulations.\xa0 NIH may terminate awards under certain circumstances.\xa0 See\n     \n     2 CFR Part 200.340 Termination\n     \n    and\n     \n     NIH Grants Policy Statement Section 8.5.2 Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding of Support\n     \n    .\n    \n \n    Successful recipients under this NOFO agree that:\n    \n \n    Where the award funding involves implementing, acquiring, or upgrading health IT for activities by any funded entity, recipients and subrecipient(s) are required to: Use health IT that meets standards and implementation specifications adopted in 45 CFR part 170, Subpart B, if such standards and implementation specifications can support the activity.\xa0 Visit\n     \n     https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-D/part-170/subpart-B\n     \n    to learn more.\n    \n \n    Where the award funding involves implementing, acquiring, or upgrading health IT for activities by eligible clinicians in ambulatory settings, or hospitals, eligible under Sections 4101, 4102, and 4201 of the HITECH Act, use health IT certified under the ONC Health IT Certification Program if certified technology can support the activity. Visit\n     \n     https://www.healthit.gov/topic/certification-ehrs/certification-health-it\n     \n    to learn more.\n    \n \n    Pursuant to the Cybersecurity Act of 2015, Div. N, § 405, Pub. Law 114-113, 6 USC § 1533(d), the HHS Secretary has established a common set of voluntary, consensus-based, and industry-led guidelines, best practices, methodologies, procedures, and processes.\n    \n \n    Successful recipients under this NOFO agree that:\n    \n \n    When recipients, subrecipients, or third-party entities have:\n    \n \n \n     ongoing and consistent access to HHS owned or operated information or operational technology systems; and\n     \n \n     receive, maintain, transmit, store, access, exchange, process, or utilize personal identifiable information (PII) or personal health information (PHI) obtained from the awarding HHS agency for the purposes of executing the award.\n     \n \n \n    Recipients shall develop plans and procedures, modeled after the\n     \n     NIST Cybersecurity framework\n     \n    , to protect HHS systems and data. Please refer to\n     \n     NIH Post-Award Monitoring and Reporting\n     \n    for additional information.\n    \n \n \n   Cooperative Agreement Terms and Conditions of Award\n    \n    The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (HHS) grant administration regulations at 2 CFR Part 200, and other HHS, PHS, and NIH grant administration policies.\n    \n \n    The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the recipients is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients\' activities by involvement in and otherwise working jointly with the recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the recipients for the project as a whole, although specific tasks and activities may be shared among the recipients and NIH as defined below.\n    \n \n \n     The PD(s)/PI(s) will have the primary responsibility for:\n     \n \n \n \n     Determining and coordinating the scientific and administrative activities of the approved projects;\n     \n \n     Setting project goals and timelines;\n     \n \n     Serving on the AADCRC Steering Committee and participating in all Steering Committee activities;\n     \n \n     Accepting and implementing common guidelines approved by the Steering Committee;\n     \n \n     For clinical trials and other human subject research, implementing current Good Clinical Practice guidelines and complying with the\n      \n      NIAID Clinical Terms of Award\n      \n     ;\n     \n \n     For clinical trials in which the PD(s)/PI(s) is the IND/IDE Sponsor, having responsibilty for the development, assembly, and submission of all required regulatory documents, providing NIAID all required information in accordance to NIH clinical research guidance. This includes, but is not limited to, all communications with the FDA (or other regulatory authority) and the Institutional Review Board (IRB). If NIAID is the IND/IDE Sponsor, providing access to all necessary data and documentation to NIAID to fulfill its role.\n     \n \n     Sharing reagents and resources with other investigators funded under this NOFO as appropriate, including any scientists added via IOF support;\n     \n \n     Making data available for external checking against the original source documentation;\n     \n \n     Recipients will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and NIH policies.\n     \n \n \n \n     NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:\n     \n \n \n \n     NIAID may assign one or more Project Scientist(s) to the AADCRC program. The Project Scientist(s) will:\n      \n \n       Provide guidance and support in the design of research activities;\n       \n \n       Provide guidance and support in the execution of studies;\n       \n \n       Contribute to the analysis and publication of data;\n       \n \n       Advise in the selection of sources or resources;\n       \n \n       Advise in management and technical performance;\n       \n \n       In AADCRC centers that include clinical trials, and in some cases clinical studies, the NIAID-assigned Project Scientist will be a Medical Officer;\n       \n \n       Assist in planning of the meetings and teleconferences of the Steering Committee and subcommittees, and ensure coordination of Steering Committee activities and implementation of its recommendations, decisions, and policies.\n       \n \n       All NIAID staff will be non-voting members of the Steering Committee.\n       \n \n \n \n \n \n     Clinical Research Oversight\n     \n \n \n \n \n      Protocol Development, Review and Approval:\n      \n     The NIAID Project Scientist will participate in the development, review and approval of all clinical research protocols supported by this NOFO.\n     \n \n     In some cases,\xa0the NIAID-assigned Project Scientist will be a physician who may also assume the role of Medical Monitor of a clinical study or trial.\n     \n \n \n      IND/IDE:\n      \n     NIAID retains the right to have NIAID serve as the IND/IDE sponsor for trials involving the use of investigational products.\n     \n \n \n      Monitoring Boards and Safety Reporting:\n      \n     NIAID Project Scientists will facilitate and provide oversight of the review and reporting of data to DAIT monitoring committees and Data Safety and Monitoring Boards.\n     \n \n \n      Study Termination:\n      \n     NIAID reserves the right to terminate or curtail a clinical study or clinical trial for any of the following reasons:\n      \n \n       risk to subject safety;\n       \n \n       the scientific question is no longer relevant, or the objectives will not be met;\n       \n \n       failure to comply with Good Clinical Practices, Federal Regulations, or Terms and Conditions of Award;\n       \n \n       occurrence of unforeseen drug safety issues or data from preclinical studies indicate a presence of unanticipated toxicity;\n       \n \n       risks that cannot be adequately quantified;\n       \n \n       failure to remedy deficiencies identified through site monitoring;\n       \n \n       substandard data; inadequate progress in fulfilling the research agenda;\n       \n \n       slow accrual; or\n       \n \n       reaching a major study endpoint substantially before schedule with persuasive statistical significance.\n       \n \n \n \n \n      Access to Data:\n      \n     The NIAID Project Scientist or designee will have access to all data generated under this cooperative agreement and may review the data as recorded on the case report forms or in a database. NIAID staff may use information obtained from the data for the preparation of internal reports on the activities of the study.\n     \n \n     Additionally, an agency program official or IC program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.\n     \n \n \n \n     Areas of Joint Responsibility include:\n     \n \n \n \n     Establishing a Steering Committee consisting of the PD(s)/PI(s) of each AADCRC and NIH Project Scientists from NIAID. The NIH Program Officer will be an optional attendee. The Steering Committee’s responsibilities include facilitating collaborative projects,\xa0organizing the yearly IOF competition (establishing goals, guidelines and evaluation criteria, evaluating proposed projects, and proposing funding plans), setting the agenda for an annual face-to-face AADCRC scientific meeting, establishing an AADCRC policy to promote resource sharing among AADCRCs and outside collaborators, and proposing AADCRC-centered sessions for national and international scientific meetings.\n     \n \n \n    Each AADCRC Center will have one voting member on the Steering Committee; in the case of multi-PI centers, all PIs/PDs will be Steering Committee members, but must share one vote. NIAID Project Scientists and the NIH Program Officer will be non-voting members of the Steering Committee and participate in all Steering Committee activities. A chair will be elected by the majority of vote among the voting members of the Steering Committee. The Steering Committee will make decisions by majority vote. The Steering Committee will meet by teleconference twice a year and at a face-to-face meeting once a year.\n    \n \n \n     Collaboratively facilitating the conduct, progress and monitoring of the studies supported by the award.\n     \n \n     Fostering collaborations between AADCRCs.\n     \n \n \n \n     Dispute Resolution:\n     \n \n \n    Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between recipients and NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual recipient. This special dispute resolution procedure does not alter the recipient\'s right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and HHS regulation 45 CFR Part 16.\n    \n \n \n \n    3. Data Management and Sharing\n    \n \n    Consistent with the 2023 NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the\n     \n     NIH Grants Policy Statement\n     \n    . Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.\n    \n \n \n   4. Reporting\n    \n \n     When multiple years are involved, recipients will be required to submit the\n      \n      Research Performance Progress Report (RPPR)\n      \n     annually and financial statements as required in the\n      \n      NIH Grants Policy Statement Section 8.4.1 Reporting\n      \n     . To learn more about post-award monitoring and reporting, see the NIH Grants & Funding website, see\n      \n      Post-Award Monitoring and Reporting\n      \n     .\n     \n \n \n \n \n    Progress reports should briefly describe status of pilot projects, including data and safety monitoring, and should notify NIH of serious adverse events and unanticipated problems.\n    \n \n \n \n    A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the\n     \n     NIH Grants Policy Statement Section 8.6 Closeout\n     \n    . NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301.',
    "RFA-AI-24-079: Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional) Section IV. Application and Submission Information\n    \n \n \n \n    1. Requesting an Application Package\n    \n \n    The application forms package specific to this opportunity must be accessed through ASSIST or an institutional system-to-system solution. A button to apply using ASSIST is available in Part 1 of this NOFO. See the administrative office for instructions if planning to use an institutional system-to-system solution.\n    \n \n \n \n    2. Content and Form of Application Submission\n    \n \n    It is critical that applicants follow the Multi-Project (M) Instructions in the\n     \n     How to Apply - Application Guide\n     \n    , except where instructed in this notice of funding opportunity to do otherwise and where instructions in the\n     \n     How to Apply - Application Guide\n     \n    are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the\n     \n     How to Apply - Application Guide\n     \n    is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.\n    \n \n \n \n    Letter of Intent\n    \n \n    Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.\n    \n \n    By the date listed in\n     \n     Part 1. Overview Information\n     \n    , prospective applicants are asked to submit a letter of intent that includes the following information:\n    \n \n \n     Descriptive title of proposed activity\n     \n \n     Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)\n     \n \n     Names of other key personnel\n     \n \n     Participating institution(s)\n     \n \n     Number and title of this funding opportunity\n     \n \n \n    The letter of intent should be sent to:\n    \n \n    Poonam Tewary, PhD\n     \n    Telephone: 240-532-9777\n     \n    Email:\n     \n \n      [email\xa0protected]\n      \n \n \n \n \n \n \n    Page Limitations\n    \n \n    All page limitations described in the\n     \n     How to Apply- Application Guide\n     \n    and the\n     \n     Table of Page Limits\n     \n    must be followed.\n    \n \n \n \n \n \n \n       Component\n       \n \n       Component Type for Submission\n       \n \n       Page Limit\n       \n \n       Required/Optional\n       \n \n       Minimum\n       \n \n       Maximum\n       \n \n \n \n \n \n       Overall\n       \n \n       Overall\n       \n \n       12\n       \n \n       Required\n       \n \n       1\n       \n \n       1\n       \n \n \n \n       Admin Core\n       \n \n       Admin Core\n       \n \n       6\n       \n \n       Required\n       \n \n       1\n       \n \n       1\n       \n \n \n \n       Data Stewardship Core\n       \n \n       Data Core\n       \n \n       6\n       \n \n       Required\n       \n \n       1\n       \n \n       1\n       \n \n \n \n       Clinical Core\n       \n \n       Clinical Core\n       \n \n       6\n       \n \n       Optional\n       \n \n       0\n       \n \n       1\n       \n \n \n \n       Scientific Core\n       \n \n       Scientific Core\n       \n \n       6\n       \n \n       Optional\n       \n \n       0\n       \n \n       2\n       \n \n \n \n       Research Project\n       \n \n       Project\n       \n \n       12\n       \n \n       Required\n       \n \n       2\n       \n \n       NA\n       \n \n \n \n \n \n \n    Instructions for the Submission of Multi-Component Applications\n    \n \n \n \n    The following section supplements the instructions found in\n     \n     How to Apply- Application Guide\n     \n    and should be used for preparing a multi-component application.\n    \n \n \n \n    The application should consist of the following components:\n    \n \n    Overall: required, 1\n    \n \n \n     Administrative Core: required, 1\n     \n \n     Data Stewardship Core: required: 1, the Data Stewardship Core must support all Research Projects, and will support other Scientific/Clinical Core(s), as needed\n     \n \n     Clinical Core: optional,\xa0maximum 1, the Clinical Core must support at least two Research Projects\n     \n \n     Scientific Core: optional, maximum 2, each Scientific Core must support at least two Research Projects\n     \n \n     Research Projects: required, minimum 2, no maximum\n     \n \n \n \n \n    Overall Component\n    \n \n    When preparing the application, use Component Type ‘Overall’.\n    \n \n    All instructions in the\n     \n     How to Apply - Application Guide\n     \n    must be followed, with the following additional instructions, as noted.\n    \n \n \n \n    SF424(R&R) Cover (Overall)\n    \n \n    Complete entire form.\n    \n \n \n \n    PHS 398 Cover Page Supplement (Overall)\n    \n \n    Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.\n    \n \n \n \n    Research & Related Other Project Information (Overall)\n    \n \n    Follow standard instructions.\n    \n \n \n \n    Project/Performance Site Locations (Overall)\n    \n \n    Enter primary site only.\n    \n \n \n \n \n     A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.\n     \n \n \n \n \n    Research and Related Senior/Key Person Profile (Overall)\n    \n \n    Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this NOFO) for the entire application.\n    \n \n \n \n \n     A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.\n     \n \n \n \n \n    Budget (Overall)\n    \n \n    The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.\n    \n \n \n \n \n     A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.\n     \n \n \n \n \n    PHS 398 Research Plan (Overall)\n    \n \n \n \n \n     Specific Aims:\n     \n    List in priority order, the broad, long-range objectives and goals of the proposed Center. Concisely describe the hypothesis or hypotheses to be tested.\n    \n \n \n \n \n     Research Strategy:\n     \n    Describe the focus of the research Center. This narrative section should summarize the overall research strategy for the multi-component application. The multi-component application should be viewed as a confederation of interrelated Research Projects, each capable of standing on its own scientific merit, but complementary to one another. This is an important section, for it provides the group of investigators an opportunity to give conceptual wholeness to the overall Center\xa0by giving a statement of the general problem area and by laying out a broad strategy for attacking the problem. As the strategy develops, each Research Project and Core should be cited briefly as to its place in the overall scheme. To help achieve the NOFO’s objective, it is recommended, but not required, to draft the applications along the lines of either of the two models: the Pathway Focus (Model A) or Clinical Intervention/Observation Focus (Model B) as described under Part 2, Section I.\n    \n \n    To highlight Center synergy, describe how the individual components will be coordinated and work together to address the overall goals and aims of the Center. Include a schematic overview of the interactions and collaborations among the components and indicate collaborations among members and relevant publications co-authored by members of the Center. Center synergy may also be addressed in other sections of the application, as appropriate. Discuss the role of all Research Projects and Cores in the Overall Research Strategy of the application. Describe how the integration of the individual Research Projects into a single Center benefits the objectives more than pursuing each project independently. For renewal applications, describe the impact that the Center’s prior accomplishments have had on the field of asthma and/or allergic disease.\n    \n \n    For individual Research Projects and Cores that will be continued as part of a renewal application, additional details of progress made during the prior funding period should be provided in the Research Strategy within each Research Project and/or Core.\n    \n \n \n \n \n \n \n \n \n     Resource Sharing Plan\n     \n    :\n     \n    Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the\n     \n     How to Apply - Application Guide\n     \n    .\n    \n \n \n \n \n     Other Plan(s):\n     \n \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed, with the following additional instructions:\n    \n \n \n \n \n     All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.\n     \n \n     Recipients are encouraged to deposit data into\xa0the\n      \n      ImmPort database\n      \n     .\n     \n \n \n \n \n \n     Appendix:\n     \n \n \n    Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in\n     \n     How to Apply- Application Guide\n     \n    ; any instructions provided here are in addition to the\n     \n     How to Apply - Application Guide\n     \n    instructions.\n    \n \n \n \n    PHS Human Subjects and Clinical Trials Information (Overall)\n    \n \n    When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the\n     \n     How to Apply - Application Guide\n     \n    , with the following additional instructions:\n    \n \n    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, there must be at least one human subjects study record using the\n     \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n    form or a\n     \n     Delayed Onset Study\n     \n    record within the application. The study record(s) must be included in the component(s) where the work is being done, unless the same study spans multiple components. To avoid the creation of duplicate study records, a single study record with sufficient information for all involved components must be included in the Overall component when the same study spans multiple components.\n    \n \n \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n \n \n    All instructions in the\n     \n     How to Apply - Application Guide\n     \n    must be followed.\n    \n \n \n \n \n     Delayed Onset Study\n     \n \n \n    Note:\n     \n     Delayed onset\n     \n    does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed.\n    \n \n \n \n    PHS Assignment Request Form (Overall)\n    \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed.\n    \n \n \n \n \n     Administrative Core\n     \n \n \n    When preparing your application, use Component Type ‘Admin Core.’\n    \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed, with the following additional instructions, as noted.\n    \n \n \n     SF424 (R&R) Cover (Administrative Core)\n     \n \n \n    Complete only the following fields:\n    \n \n \n     Applicant Information\n     \n \n     Type of Applicant (optional)\n     \n \n     Descriptive Title of Applicant’s Project\n     \n \n     Proposed Project Start/Ending Dates\n     \n \n \n \n     PHS 398 Cover Page Supplement (Administrative Core)\n     \n \n \n    Enter Human Embryonic Stem Cells in each relevant component.\n    \n \n \n     Research & Related Other Project Information (Administrative Core)\n     \n \n \n \n     Human Subjects:\n     \n    Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.\n    \n \n \n     Vertebrate Animals:\n     \n    Answer only the ‘Are Vertebrate Animals Used?’ question.\n    \n \n \n     Project Narrative:\n     \n    Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.\n    \n \n \n     Project/Performance Site Location(s) (Administrative Core)\n     \n \n \n    List all performance sites that apply to the specific component.\n    \n \n \n     Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.\n     \n \n \n \n     Research & Related Senior/Key Person Profile (Administrative Core)\n     \n \n \n \n     In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Core Lead’ and provide a valid eRA Commons ID in the Credential field.\n     \n \n     In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.\n     \n \n     Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.\n     \n \n     If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.\n     \n \n     For institutions/organizations proposing a single PD/PI, the PD/PI will serve as the Administrative Core Lead. For institutions/organizations proposing multiple PD(s)/PI(s), the Contact PD/PI must serve as the Administrative Core Lead.\n     \n \n \n \n     Budget (Administrative Core)\n     \n \n \n    Budget forms appropriate for the specific component will be included in the application package.\n    \n \n    In the budget, include funding for the overall administrative efforts, administrative services, expenses for publications demonstrating collaborative efforts, and communication expenses.\n    \n \n \n     Infrastructure and Opportunity Fund (IOF)\n     \n    : Propose funds for the IOF within the Administrative Core component; the IOF budget is not expected to exceed $350K in direct costs. This will be awarded to one recipient organization that will be selected by NIAID post-award to manage the fund. Include IOF costs as a single line item in the Other Direct Costs Category of the Administrative Core Budget. A part of the IOF budget, direct costs proposed for an IOF administrator may be requested in the Personnel category for a maximum of 0.5 person months and must comply with NIH grants policy. F&A Costs will be applied in accordance with NIH grants policy.\n    \n \n    Include travel funds for the PD(s)/PI(s) and subproject PD(s)/PI(s) to attend an annual AADCRC Scientific and Steering Committee meeting. The two-day meeting will be held each year in or near Rockville, Maryland.\n    \n \n \n     Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.\n     \n \n \n \n     PHS 398 Research Plan (Administrative Core)\n     \n \n \n \n     Specific Aims:\n     \n    List in priority order the proposed activities and services of the Administrative Core. Describe the work to be completed to address issues of Center coordination, communication, management, and administering the IOF. Testing of scientific hypotheses should not be proposed within a Core.\n    \n \n \n     Research Strategy:\n     \n    A fully developed and well-described Administrative Core plan is required.\n    \n \n    Describe and justify the operational plan and organizational structure of the proposed multi-component application. Include plans on how the PD(s)/PI(s) will interact and coordinate with Project/Core Leaders to identify and resolve problems and establish a strong collaborative environment for the Center. Provide an administrative plan that includes a discussion of the structure and roles of administrative staff, including the functions to be performed; how fiscal and other resources will be prioritized, allocated, and managed; how communications, group meetings, and teleconferences will be facilitated; how conflict resolution will be attained; and how research related travel and training will be managed. Describe how the Core’s administrative, management, and leadership capabilities provide for: internal quality control of on-going research, management of day-to-day program activities, management of contractual agreements, fair communication and cooperation among program leaders and/or program investigators, and development of scientific meetings, as applicable.\xa0Present a leadership succession plan.\n    \n \n    Provide a plan to administer the AADCRC Infrastructure and Opportunity Fund (IOF), including fund disbursement, administration, and reports. Within the plan, address the following: establishing an administrative structure to manage the IOF; disbursing and tracking IOF funds under the direction of the Steering Committee; implementing plans for interacting with the institutions that will receive IOF funds, including establishing consortium agreements when applicable; and establishing procedures, formats, and timelines for reporting on the status of IOF projects and expenditures to the NIAID and the AADCRC Steering Committee.\n    \n \n \n     External Advisory Group (optional)\n     \n    : If an EAG is proposed for an individual Center, then describe the expertise and responsibilities of the potential members. Discuss how the individual Center Research Projects will be supported by the EAG.\n     \n \n    For a new application,\n     \n     do not\n     \n    contact or name potential members in the application\n     \n     .\n     \n    For a renewal application with an EAG already established, provide the names only of current EAG members in the application.\n    \n \n \n     Resource Sharing Plan:\n     \n    Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the\n     \n     How to Apply - Application Guide\n     \n    .\n    \n \n \n     Appendix:\n     \n \n \n    Only limited items are allowed in the Appendix. Follow all instructions for the\n     \n     How to Apply - Application Guide\n     \n    ; any instructions provided here are in addition to those in the\n     \n     How to Apply - Application Guide\n     \n    instructions.\n    \n \n \n     PHS Human Subjects and Clinical Trials Information (Administrative Core)\n     \n \n \n    When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the\n     \n     How to Apply - Application Guide,\n     \n    with the following additional instructions:\n    \n \n    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the\n     \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n    form or a\n     \n     Delayed Onset Study\n     \n    record.\n    \n \n \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n \n \n    All instructions in the\n     \n     How to Apply - Application Guide\n     \n    must be followed.\n    \n \n \n     Delayed Onset Study\n     \n \n \n    Note:\n     \n     Delayed onset\n     \n    does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the\n     \n     How to Apply - Application Guide\n     \n    must be followed.\n    \n \n \n     Data Stewardship Core\n     \n \n \n    When preparing your application, use Component Type ‘Data Core.’\n    \n \n    All instructions in the\n     \n     How to Apply - Application Guide\n     \n    must be followed, with the following additional instructions, as noted.\n    \n \n \n     SF424 (R&R) Cover (Data Stewardship Core)\n     \n \n \n    Complete only the following fields:\n    \n \n \n     Applicant Information\n     \n \n     Type of Applicant (optional)\n     \n \n     Descriptive Title of Applicant’s Project\n     \n \n     Proposed Project Start/Ending Dates\n     \n \n \n \n     PHS 398 Cover Page Supplement (Data Stewardship Core)\n     \n \n \n    Enter Human Embryonic Stem Cells in each relevant component.\n    \n \n \n     Research & Related Other Project Information (Data Stewardship Core)\n     \n \n \n \n     Human Subjects:\n     \n    Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.\n    \n \n \n     Vertebrate Animals:\n     \n    Answer only the ‘Are Vertebrate Animals Used?’ question.\n    \n \n \n     Project Narrative:\n     \n    Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.\n    \n \n \n     Facilities & Other Resources:\n     \n    Describe the facilities provided by the Core, as applied to procedures and techniques provided, as well as quality control.\n    \n \n \n     Project/Performance Site Location(s) (Data Stewardship Core)\n     \n \n \n    List all performance sites that apply to the specific component.\n    \n \n \n     Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.\n     \n \n \n \n     Research & Related Senior/Key Person Profile (Data Stewardship Core)\n     \n \n \n \n     In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Core Lead’ and provide a valid eRA Commons ID in the Credential field.\n     \n \n     In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.\n     \n \n     Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.\n     \n \n     If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.\n     \n \n \n \n     Budget (Data Stewardship Core)\n     \n \n \n    Budget forms appropriate for the specific component will be included in the application package.\n    \n \n    Request funds to support central data management (database establishment, data management and cleaning, data storage, database security) for the entire awarded U19 Cooperative Agreement to all researchers within the applicant group.\n    \n \n    In case the statistical design and analysis of data for at least two Research Projects is to be conducted by this Core, request funds to support appropriate biostatistical personnel and equipment use effort.\n    \n \n    Request funds to support the required timely submission of data, meta-data and data analyses to the ImmPort database or other public databases as appropriate.\n    \n \n    The percentage of total funds that will be required to support each component Research Project or Core that will utilize the Data Stewardship Core should also be presented. This information should be included in the Core’s budget justification for Year 1.\n    \n \n    For all clinical trials, NIAID will provide a Data and Safety Monitoring Board (DSMB). Therefore, the applicant does not need to include or budget for DSMB expenses.\n    \n \n \n     Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.\n     \n \n \n \n     PHS 398 Research Plan (Data Stewardship Core)\n     \n \n \n \n     Specific Aims:\n     \n    List in priority order the broad, long-range activities and services of the proposed Core. In addition, state the Core’s relationship to the Center’s goals and how the Core relates to all the activities of individual Research Projects in the application. Testing of scientific hypotheses should not be proposed within a Core.\n    \n \n \n     Research Strategy:\n     \n \n \n    Describe and justify the overall function of the required Data Stewardship Core. Describe how the services of this Core (including procedures, techniques and quality control) will support all proposed\xa0Research Projects and Scientific and/or Clinical Cores,\xa0and advance the outcomes from the proposed research Center.\n    \n \n    Describe how the Data Stewardship Core will facilitate the harmonization of data collection and analysis services across all Research Projects and Scientific/Clinical Cores, as needed.\n    Discuss how the Core will support data management by providing appropriate team expertise.  Describe the plans for development of harmonized protocols, including selection and use of common data elements, if applicable. Explain the processes, procedures, methods and plans to provide bioinformatics infrastructure support for Center-wide database establishment, data cleaning and tracking, information management, curation, data monitoring, data storage and quality control. Outline how the Core will promote the exchange of information among all recipients of this NOFO.\n    \n \n    If the Data Stewardship Core will support the statistical design and data analyses for Research Projects and/or a Clinical or Scientific Core, provide general descriptions of statistical approaches to be used. However, specific statistical analyses addressing scientific hypotheses should be described within each of the Research Projects or within the Clinical or Scientific Core, whichever is applicable.\n    \n \n    Note that information requested here for this Core should not duplicate the information provided in the Data Management and Sharing Plan. Place information regarding plans to comply with the NIH Data Management and Sharing Policy in the Data Management and Sharing Plan attachment in the “Other Plan(s)” section of the Overall component.\n    \n \n \n     Note\n     \n    : Specific details for clinical trials and studies will be captured using the PHS Human Subjects and Clinical Trials Information Form. Do not duplicate information requested under the PHS Human Subjects and Clinical Trials Information Forms.\n    \n \n \n     Resource Sharing Plan:\n     \n    Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the\n     \n     How to Apply - Application Guide\n     \n    .\n    \n \n \n     Appendix:\n     \n \n \n    Only limited items are allowed in the Appendix. Follow all instructions for the\n     \n     How to Apply- Application Guide\n     \n    ; any instructions provided here are in addition to those in the\n     \n     How to Apply- Application Guide\n     \n    instructions.\n    \n \n \n     PHS Human Subjects and Clinical Trials Information (Data Stewardship Core)\n     \n \n \n    When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the\n     \n     How to Apply- Application Guide,\n     \n    with the following additional instructions:\n    \n \n    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the\n     \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n    form or a\n     \n     Delayed Onset Study\n     \n    record.\n    \n \n \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed.\n    \n \n \n     Delayed Onset Study\n     \n \n \n    Note:\n     \n     Delayed onset\n     \n    does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed.\n    \n \n \n     Clinical Core\n     \n \n \n    When preparing your application, use Component Type ‘Clinical Core.’\n    \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed, with the following additional instructions, as noted.\n    \n \n \n     SF424 (R&R) Cover (Clinical Core)\n     \n \n \n    Complete only the following fields:\n    \n \n \n     Applicant Information\n     \n \n     Type of Applicant (optional)\n     \n \n     Descriptive Title of Applicant’s Project\n     \n \n     Proposed Project Start/Ending Dates\n     \n \n \n \n     PHS 398 Cover Page Supplement (Clinical Core)\n     \n \n \n    Enter Human Embryonic Stem Cells in each relevant component.\n    \n \n \n     Research & Related Other Project Information (Clinical Core)\n     \n \n \n \n     Human Subjects:\n     \n    Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.\n    \n \n \n     Vertebrate Animals:\n     \n    Answer only the ‘Are Vertebrate Animals Used?’ question.\n    \n \n \n     Project Narrative:\n     \n    Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.\n    \n \n \n     Facilities & Other Resources:\n     \n    Describe the facilities provided by the Core, as applied to procedures and techniques provided, as well as quality control.\n    \n \n \n     Project/Performance Site Location(s) (Clinical Core)\n     \n \n \n    List all performance sites that apply to the specific component.\n    \n \n \n     Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.\n     \n \n \n \n     Research & Related Senior/Key Person Profile (Clinical Core)\n     \n \n \n \n     In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Core Lead’ and provide a valid eRA Commons ID in the Credential field.\n     \n \n     In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.\n     \n \n     Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.\n     \n \n     If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.\n     \n \n     Within the biosketches, highlight the expertise of the Clinical Core Lead to guide and/or assist in the development and preparation of documentation required for clinical research, as well as experience with regulatory activities, including IND/IDE submissions (if applicable), recruitment and retention of study participants, medical monitoring, and safety oversight and reporting.\n     \n \n \n \n     Budget (Clinical Core)\n     \n \n \n    Budget forms appropriate for the specific component will be included in the application package.\n    \n \n    For Year 1, outline the percentage of total funds that will be required to support each component Research Project that will utilize the Clinical Core\n    \n \n    If a clinical trial is proposed, include costs for a medical monitor.\n    \n \n    For all clinical trials, NIAID will provide a Data and Safety Monitoring Board (DSMB). Therefore, do not include or budget for DSMB expenses.\n    \n \n \n     Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.\n     \n \n \n \n     PHS 398 Research Plan (Clinical Core)\n     \n \n \n \n     Specific Aims:\n     \n    List in priority order the broad, long-range activities and services of the proposed Clinical Core. In addition, state the Core’s relationship to the Center’s goals and how the Core relates to two or more individual Research Projects in the application. Testing of scientific hypotheses should not be proposed within a Core.\n    \n \n \n     Research Strategy:\n     \n \n \n    Describe how the Clinical Core will support at least one of two purposes: 1) recruit and characterize human subjects and collect appropriate biosamples in support of at least two Research Project(s), and/or 2) conduct one or more single-site pilot clinical trials or clinical studies in support of at least two Research Projects.\n    \n \n \n     Describe how the proposed Clinical Core activities will contribute to meeting the Center’s goals and objectives and explain why the Core resources are not otherwise available.\n     \n \n     Describe how resource utilization will be allocated and/or prioritized, if applicable, to support the Center. Indicate the specific projects to be supported by the Clinical Core.\n     \n \n     Describe the services provided by the Core (including procedures, techniques, and quality control).\n     \n \n \n    If the Clinical Core proposes single site pilot clinical trials and/or studies designed only to collect and provide samples for two or more Research Projects, describe the following aspects of the proposed trial(s)/study(ies):\n    \n \n \n     Discuss the rationale and process for the selection, recruitment and retention of the participant population, choice of intervention (if applicable), choice of study sites, duration, plans for trial management and schedule of events.\n     \n \n     Discuss the trial/study's feasibility, difficulties that may be encountered, and offer alternative approaches to be implemented, if needed, include general concepts for sample size determinations and statistical methodologies, but, particularly for pilot clinical trials, provide study-specific details in the PHS Human Subjects and Clinical Trial Information Forms.\n     \n \n \n \n     Note:\n     \n    If a clinical trial/study is included in a Research Project (and not as a Clinical Core), then the above information should appear as part of that Research Project.\n    \n \n \n     Note:\n     \n    Specific details for trials and studies will be captured using the PHS Human Subjects and Clinical Trials Information Form. Do not duplicate information requested under the PHS Human Subjects and Clinical Trials Information Forms.\n    \n \n \n     Resource Sharing Plan:\n     \n    Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the\n     \n     How to Apply- Application Guide\n     \n    .\n    \n \n \n     Appendix:\n     \n \n \n    Only limited items are allowed in the Appendix. Follow all instructions for the\n     \n     How to Apply- Application Guide\n     \n    ; any instructions provided here are in addition to those in the\n     \n     How to Apply- Application Guide\n     \n    instructions.\n    \n \n \n     PHS Human Subjects and Clinical Trials Information (Clinical Core)\n     \n \n \n    When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the\n     \n     How to Apply- Application Guide,\n     \n    with the following additional instructions:\n    \n \n    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the\n     \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n    form or a\n     \n     Delayed Onset Study\n     \n    record.\n    \n \n \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed.\n    \n \n \n     Delayed Onset Study\n     \n \n \n    Note:\n     \n     Delayed onset\n     \n    does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed.\n    \n \n \n     Scientific Core\n     \n \n \n    When preparing your application, use Component Type ‘Scientific Core.’\n    \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed, with the following additional instructions, as noted.\n    \n \n \n     SF424 (R&R) Cover (Scientific Core)\n     \n \n \n    Complete only the following fields:\n    \n \n \n     Applicant Information\n     \n \n     Type of Applicant (optional)\n     \n \n     Descriptive Title of Applicant’s Project\n     \n \n     Proposed Project Start/Ending Dates\n     \n \n \n \n     PHS 398 Cover Page Supplement (Scientific Core)\n     \n \n \n    Enter Human Embryonic Stem Cells in each relevant component.\n    \n \n \n     Research & Related Other Project Information (Scientific Core)\n     \n \n \n \n     Human Subjects:\n     \n    Answer only the ‘Are Human Subjects Involved?’ and ‘Is the Project Exempt from Federal regulations?’ questions.\n    \n \n \n     Vertebrate Animals:\n     \n    Answer only the ‘Are Vertebrate Animals Used?’ question.\n    \n \n \n     Project Narrative:\n     \n    Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.\n    \n \n \n     Facilities & Other Resources:\n     \n    Describe the facilities provided by the Core, as applied to procedures and techniques provided, as well as quality control.\n    \n \n \n     Project/Performance Site Location(s) (Scientific Core)\n     \n \n \n    List all performance sites that apply to the specific component.\n    \n \n \n     Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.\n     \n \n \n \n     Research & Related Senior/Key Person Profile (Scientific Core)\n     \n \n \n \n     In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Core Lead’ and provide a valid eRA Commons ID in the Credential field.\n     \n \n     In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.\n     \n \n     Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.\n     \n \n     If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.\n     \n \n \n \n     Budget (Scientific Core)\n     \n \n \n    Budget forms appropriate for the specific component will be included in the application package.\n    \n \n    For Year 1, outline the percentage of total funds that will be required to support each component Research Project that will utilize the Scientific Core.\n    \n \n \n     Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.\n     \n \n \n \n     PHS 398 Research Plan (Scientific Core)\n     \n \n \n \n     Specific Aims:\n     \n \n \n \n     Discuss the Core’s relationship to the Center’s goals and how the Core relates to two or more individual Research Projects in the application. Testing of scientific hypotheses should not be proposed within a Core.\n     \n \n \n \n     Research Strategy:\n     \n \n \n \n     Describe how the proposed Scientific Core activities (including procedures, techniques and quality control) will contribute to meeting the Center’s goals and objectives and explain why the Core resources are not otherwise available.\n     \n \n     Describe how resource utilization will be allocated and/or prioritized, if applicable, to support the Center.\n     \n \n \n    Indicate the specific Research Projects to be supported by the Scientific Core. Describe the interactions of the Core with each of the Research Projects.\n    \n \n \n     Resource Sharing Plan:\n     \n    Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the\n     \n     How to Apply- Application Guide\n     \n    .\n    \n \n \n     Appendix:\n     \n \n \n    Only limited items are allowed in the Appendix. Follow all instructions for the\n     \n     How to Apply- Application Guide\n     \n    ; any instructions provided here are in addition to those in the\n     \n     How to Apply- Application Guide\n     \n    instructions.\n    \n \n \n     PHS Human Subjects and Clinical Trials Information (Scientific Core)\n     \n \n \n    When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the\n     \n     How to Apply- Application Guide,\n     \n    with the following additional instructions:\n    \n \n    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the\n     \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n    form or a\n     \n     Delayed Onset Study\n     \n    record.\n    \n \n \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed.\n    \n \n \n     Delayed Onset Study\n     \n \n \n    Note:\n     \n     Delayed onset\n     \n    does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed.\n    \n \n \n     Research Project\n     \n \n \n    When preparing your application, use Component Type ‘Project.’\n    \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed, with the following additional instructions, as noted.\n    \n \n \n     SF424 (R&R) Cover (Research Project)\n     \n \n \n    Complete only the following fields:\n    \n \n \n     Applicant Information\n     \n \n     Type of Applicant (optional)\n     \n \n     Descriptive Title of Applicant’s Project\n     \n \n     Proposed Project Start/Ending Dates\n     \n \n \n \n     PHS 398 Cover Page Supplement (Research Project)\n     \n \n \n    Enter Human Embryonic Stem Cells in each relevant component.\n    \n \n \n     Research & Related Other Project Information (Research Project)\n     \n \n \n \n     Human Subjects:\n     \n    Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.\n    \n \n \n     Vertebrate Animals:\n     \n    Answer only the ‘Are Vertebrate Animals Used?’ question.\n    \n \n \n     Project Narrative:\n     \n    Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.\n    \n \n \n     Project/Performance Site Location(s) (Research Project)\n     \n \n \n    List all performance sites that apply to the specific component.\n    \n \n \n     Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.\n     \n \n \n \n     Research & Related Senior/Key Person Profile (Research Project)\n     \n \n \n \n     In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.\n     \n \n     In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.\n     \n \n     Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.\n     \n \n     If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.\n     \n \n     Within the biosketches, highlight the experience and expertise of the Research Project Lead and key personnel in regulatory activities, including IND/IDE submissions, safety oversight and reporting.\n     \n \n \n \n     Budget (Research Project)\n     \n \n \n    Budget forms appropriate for the specific component will be included in the application package.\n    \n \n    In single PD/PI applications, the PD/PI must also lead at least one Research Project and is required to commit an overall minimum of 2 person months in AADCRC activities. In multi-PD/PI applications, every PD/PI must lead a Research Project or Core, with at least one of the PD(s)/PI(s) leading a Research Project and committing an overall minimum of 2 person months to AADCRC activities.\n    \n \n    Include costs to support statistical design/support, data collection and analysis if those are not included in one of the Cores.\n    \n \n    If the Research Project involves a pilot clinical trial or a clinical observational study:\n    \n \n \n     Include costs for clinical site monitoring, medical monitoring, project management, and quality assurance of the proposed pilot clinical trials or observational clinical studies in the application budget. Alternatively, these costs can be incorporated into the budget of a Clinical Core, provided that specific cross-references are made to clarify how these necessary functions will be supported.\n     \n \n \n    Note: For all clinical trials, NIAID will provide a Data and Safety Monitoring Board (DSMB). Therefore, do not include or budget for DSMB expenses.\n    \n \n \n     Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.\n     \n \n \n \n     PHS 398 Research Plan (Research Project)\n     \n \n \n \n     Specific Aims:\n     \n \n \n \n     List, in priority order, the objectives and goals of the proposed project.\n     \n \n     Concisely describe the hypothesis or hypotheses to be tested. In addition, state the individual Research Project's relationship to the Center’s goals and how it relates to other projects or Cores.\n     \n \n \n \n     Research Strategy:\n     \n \n \n \n     Describe how the proposed research will contribute to meeting the Center’s goals and objectives and indicate the project's relevance to the primary theme of the application.\n     \n \n     Explain the rationale for selecting the methods to accomplish the specific aims of the Research Project.\n     \n \n     Provide a detailed timeline for the study supporting completion within the funding period.\n     \n \n \n \n     Clinical Trials\n     \n \n \n    The Approach section of a pilot clinical trial project should address the following aspects of the proposed trial(s):\n    \n \n \n     Discuss the rationale for the proposed approach for the problems being studied.\n     \n \n     Describe the design of the proposed trial, include rationale for the\xa0selection of the participant population, choice of intervention (if applicable), duration, and schedule of events.\n     \n \n     Discuss each trial’s feasibility.\n     \n \n     Include a plan for the management of the pilot clinical trial that offers description of personnel involved in 1) conducting the trial, and 2) data entry and interactions with the activities of the Data Stewardship Core.\n     \n \n     Include general concepts for sample size determinations and statistical methodologies, but provide trial-specific details in the PHS Human Subjects and Clinical Trial Information Forms.\n     \n \n \n    Note: Specific details for each trial will be captured using the PHS Human Subjects and Clinical Trials Information Forms. Do not duplicate information requested under the PHS Human Subjects and Clinical Trials Information Forms.\n    \n \n \n     Clinical studies\n     \n \n \n    For applications proposing one or more clinical studies (observational studies with no interventions and involving only minimal risk procedures or cross-sectional studies), the Approach section of the clinical study project should address the following aspects of the study:\n    \n \n \n     Describe the design of the proposed study, include rationale for the selection of the participant population, choice of outcomes, duration, and schedule of events.\n     \n \n     Discuss each study's feasibility. Include a plan for the management of the clinical study that offers description of personnel involved in conducting the study, personnel involved in data entry, and the personnel involved in statistical analysis. Describe the interactions between these teams and the Data Stewardship Core.\n     \n \n     Include general concepts for sample size determinations and statistical methodologies, but provide study-specific details in the PHS Human Subjects Information Forms.\n     \n \n     Describe the timeline for protocol development, the plan for study implementation, the plan for evaluation of proposed study site(s), and plans for management and analysis of study data.\n     \n \n     For observational or cross-sectional clinical studies, describe the data analyses and statistical approach for the proposed study design and methods used to assign participants.\n     \n \n \n    Note: Specific details for each study will be captured using the PHS Human Subjects Information Form. Do not duplicate information requested under the PHS Human Subjects Information Forms.\n    \n \n \n     Projects obtaining human samples from non-AADCRC-supported clinical studies or trials:\n     \n \n \n    For projects that plan to obtain human samples derived from clinical studies or clinical trials that are planned, ongoing, or completed and are or have been sponsored by sources other than the AADCRC, the information in the Approach section should include the following:\n    \n \n \n     Study title\n     \n \n     Study objectives (primary and secondary)\n     \n \n     Study population(s) with clear description of clinical phenotypes\n     \n \n     Key design features, including primary and secondary endpoints, comparison/control groups\n     \n \n     Sample size calculations and statistical analysis plans as they pertain to the questions posed by the AADCRC study that will utilize the parent study/trial samples\n     \n \n     Study duration and timeline (if a planned or an ongoing study)\n     \n \n \n \n     Non-clinical research\n     \n \n \n \n     Describe the research design conceptual procedures and analyses to be used to accomplish the specific aims of the project.\n     \n \n     In the rare instances where animal models are proposed, justify the models and describe how the findings could be translated into human research and how they associate with the proposed clinical project(s).\n     \n \n     Provide a tentative timetable for the project.\n     \n \n     If animal studies are included, describe the relevance of the proposed animal model(s) to human asthma and/or allergic diseases. Describe the scientific potential for findings in animals to translate to human disease and appropriately justify the use of animal models if similar data could be obtained from human studies.\n     \n \n \n \n     Letters of Support:\n     \n    For Projects obtaining human samples from non-AADCRC-supported clinical studies or trials, include documentation of the ability to acquire human samples, including written agreements between the PD(s)/PI(s), the applicant institution, the clinical study/trial sponsor(s), including drug companies, if applicable, and the IND/IDE sponsor (if not one of the above) to be used in the studies proposed by the application is required. A statement is required that the subjects from whom samples were obtained from the parent clinical study/trial not supported by the proposed AADCRC project have given informed consent/assent and the material they have provided can be used by the AADCRC project.\n    \n \n \n     Resource Sharing Plan:\n     \n    Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the\n     \n     How to Apply- Application Guide\n     \n    .\n    \n \n \n     Appendix:\n     \n \n \n    Only limited items are allowed in the Appendix. Follow all instructions for the\n     \n     How to Apply- Application Guide\n     \n    ; any instructions provided here are in addition to those in the\n     \n     How to Apply- Application Guide\n     \n    instructions.\n    \n \n \n     PHS Human Subjects and Clinical Trials Information (Research Project)\n     \n \n \n    When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the\n     \n     How to Apply- Application Guide,\n     \n    with the following additional instructions:\n    \n \n    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the\n     \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n    form or a\n     \n     Delayed Onset Study\n     \n    record.\n    \n \n \n     Study Record: PHS Human Subjects and Clinical Trials Information\n     \n \n \n    All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed with the following additional instructions:\n    \n \n \n     Section 2 - Study Population Characteristics\n     \n \n \n \n     2.5 - Recruitment and Retention Plan\n     \n \n \n    Describe actions to be taken to address problems with recruitment of study participants.\n    \n \n \n     Section 4 - Protocol Synopsis\n     \n \n \n \n     4.1 Study Design\n     \n \n \n \n     4.1.a Detailed Description\n     \n \n \n    For multi-visit studies, provide a description of the study design including the procedures and activities that can occur at each visit (schedule of events).\n    \n \n \n     Section 5 - Other Clinical Trial-related Attachments\n     \n \n \n \n     5.1 Other Clinical Trial-related Attachments\n     \n \n \n    Describe the plan to obtain required investigational agent(s).\n    \n \n    IND applications required by the FDA for any investigational agents should be obtained by applicants prior to submission of applications. Provide the IND documents with other clinical trial related attachments.\n    \n \n \n     Delayed Onset Study\n     \n \n \n    Note:\n     \n     Delayed onset\n     \n    does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the\n     \n     How to Apply- Application Guide\n     \n    must be followed.\n    \n \n \n \n    3. Unique Entity Identifier and System for Award Management (SAM)\n    \n \n    See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov\n    \n \n \n \n    4. Submission Dates and Times\n    \n \n    Part I. contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or\n     \n     Federal holiday\n     \n    , the application deadline is automatically extended to the next business day.\n    \n \n    Organizations must submit applications to\n     \n     Grants.gov\n     \n    (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the\n     \n     eRA Commons\n     \n    , NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the\n     \n     NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications\n     \n    .\n    \n \n \n     Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.\n     \n \n \n    Information on the submission process and a definition of on-time submission are provided in\n     \n     How to Apply- Application Guide.\n     \n \n \n \n \n    5. Intergovernmental Review (E.O. 12372)\n    \n \n    This initiative is not subject to\n     \n     intergovernmental review\n     \n    .\n    \n \n \n \n    6. Funding Restrictions\n    \n \n    All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the\n     \n     NIH Grants Policy Statement\n     \n    .\n    \n \n    Pre-award costs are allowable only as described in the\n     \n     NIH Grants Policy Statement\n     \n \n     Section 7.9.1 Selected Items of Cost.\n     \n \n \n \n \n    7. Other Submission Requirements and Information\n    \n \n    Applications must be submitted electronically following the instructions described in the\n     \n     How to Apply - Application Guide\n     \n    . Paper applications will not be accepted.\n    \n \n    For information on how applications will be automatically assembled for review and funding consideration after submission, refer to:\n     \n     http://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf\n     \n    .\n    \n \n \n     Applicants must complete all required registrations before the application due date.\n     \n    Section III. Eligibility Information contains information about registration.\n    \n \n    For assistance with your electronic application or for more information on the electronic submission process, visit\n     \n     How to Apply - Application Guide\n     \n    . If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the\n     \n     Dealing with System Issues\n     \n    guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.\n    \n \n \n     Important reminders:\n     \n \n \n    All PD(s)/PI(s) and component Project Leads must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form\n     \n     .\n     \n    Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.\n    \n \n    The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in\n     \n     How to Apply - Application Guide\n     \n    .\n    \n \n    See\n     \n     more tips\n     \n    for avoiding common errors.\n    \n \n \n \n    Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by the National Institute of Allergy and Infectious Diseases, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.\n    \n \n \n   Mandatory Disclosure\n    \n    Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures,\n     \n     2 CFR 200.113\n     \n    and\n     \n     NIH Grants Policy Statement Section 4.1.35\n     \n    .\n    \n \n    Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the\n     \n     HHS Office of Inspector Grant Self Disclosure Program\n     \n    at\n     \n \n      [email\xa0protected]\n      \n \n    .\n    \n \n \n \n    Post Submission Materials\n    \n \n    Applicants are required to follow the instructions for post-submission materials, as described in\n     \n     the policy\n     \n    .",
]
embeddings = model.encode(sentences)
print(embeddings.shape)
# [3, 1024]

# Get the similarity scores for the embeddings
similarities = model.similarity(embeddings, embeddings)
print(similarities.shape)
# [3, 3]

Evaluation

Metrics

Information Retrieval

• Evaluated with InformationRetrievalEvaluator

Metric	Value
cosine_accuracy@1	0.9167
cosine_accuracy@3	1.0
cosine_accuracy@5	1.0
cosine_accuracy@10	1.0
cosine_precision@1	0.9167
cosine_precision@3	0.3333
cosine_precision@5	0.2
cosine_precision@10	0.1
cosine_recall@1	0.9167
cosine_recall@3	1.0
cosine_recall@5	1.0
cosine_recall@10	1.0
cosine_ndcg@10	0.9692
cosine_mrr@10	0.9583
cosine_map@100	0.9583

Training Details

Training Dataset

Unnamed Dataset

• Size: 216 training samples
• Columns: sentence_0 and sentence_1
• Approximate statistics based on the first 216 samples:

  	sentence_0	sentence_1
  type	string	string
  details	min: 15 tokens mean: 23.54 tokens max: 47 tokens	min: 8 tokens mean: 380.44 tokens max: 512 tokens

• Samples:

  sentence_0	sentence_1
  What is the primary role of the Department of Health and Human Services?	Department of Health and Human Services
  Which services are typically provided by the Department of Health and Human Services?	Department of Health and Human Services
  What is the primary purpose of the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity?	PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Part 1. Overview Information Participating Organization(s) National Institutes of Health ( NIH ) Components of Participating Organizations National Institute of Mental Health ( NIMH ) Funding Opportunity Title National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Activity Code U19 Research Program – Cooperative Agreements Announcement Type Reissue of PAR-22-144 Related Notices April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084 . Augus...

• Loss: MatryoshkaLoss with these parameters:

  {
      "loss": "MultipleNegativesRankingLoss",
      "matryoshka_dims": [
          768,
          512,
          256,
          128,
          64
      ],
      "matryoshka_weights": [
          1,
          1,
          1,
          1,
          1
      ],
      "n_dims_per_step": -1
  }
  

Training Hyperparameters

Non-Default Hyperparameters

• eval_strategy: steps
• per_device_train_batch_size: 10
• per_device_eval_batch_size: 10
• num_train_epochs: 10
• multi_dataset_batch_sampler: round_robin

All Hyperparameters

Click to expand

• overwrite_output_dir: False
• do_predict: False
• eval_strategy: steps
• prediction_loss_only: True
• per_device_train_batch_size: 10
• per_device_eval_batch_size: 10
• per_gpu_train_batch_size: None
• per_gpu_eval_batch_size: None
• gradient_accumulation_steps: 1
• eval_accumulation_steps: None
• torch_empty_cache_steps: None
• learning_rate: 5e-05
• weight_decay: 0.0
• adam_beta1: 0.9
• adam_beta2: 0.999
• adam_epsilon: 1e-08
• max_grad_norm: 1
• num_train_epochs: 10
• max_steps: -1
• lr_scheduler_type: linear
• lr_scheduler_kwargs: {}
• warmup_ratio: 0.0
• warmup_steps: 0
• log_level: passive
• log_level_replica: warning
• log_on_each_node: True
• logging_nan_inf_filter: True
• save_safetensors: True
• save_on_each_node: False
• save_only_model: False
• restore_callback_states_from_checkpoint: False
• no_cuda: False
• use_cpu: False
• use_mps_device: False
• seed: 42
• data_seed: None
• jit_mode_eval: False
• use_ipex: False
• bf16: False
• fp16: False
• fp16_opt_level: O1
• half_precision_backend: auto
• bf16_full_eval: False
• fp16_full_eval: False
• tf32: None
• local_rank: 0
• ddp_backend: None
• tpu_num_cores: None
• tpu_metrics_debug: False
• debug: []
• dataloader_drop_last: False
• dataloader_num_workers: 0
• dataloader_prefetch_factor: None
• past_index: -1
• disable_tqdm: False
• remove_unused_columns: True
• label_names: None
• load_best_model_at_end: False
• ignore_data_skip: False
• fsdp: []
• fsdp_min_num_params: 0
• fsdp_config: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}
• fsdp_transformer_layer_cls_to_wrap: None
• accelerator_config: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}
• deepspeed: None
• label_smoothing_factor: 0.0
• optim: adamw_torch
• optim_args: None
• adafactor: False
• group_by_length: False
• length_column_name: length
• ddp_find_unused_parameters: None
• ddp_bucket_cap_mb: None
• ddp_broadcast_buffers: False
• dataloader_pin_memory: True
• dataloader_persistent_workers: False
• skip_memory_metrics: True
• use_legacy_prediction_loop: False
• push_to_hub: False
• resume_from_checkpoint: None
• hub_model_id: None
• hub_strategy: every_save
• hub_private_repo: None
• hub_always_push: False
• gradient_checkpointing: False
• gradient_checkpointing_kwargs: None
• include_inputs_for_metrics: False
• include_for_metrics: []
• eval_do_concat_batches: True
• fp16_backend: auto
• push_to_hub_model_id: None
• push_to_hub_organization: None
• mp_parameters:
• auto_find_batch_size: False
• full_determinism: False
• torchdynamo: None
• ray_scope: last
• ddp_timeout: 1800
• torch_compile: False
• torch_compile_backend: None
• torch_compile_mode: None
• dispatch_batches: None
• split_batches: None
• include_tokens_per_second: False
• include_num_input_tokens_seen: False
• neftune_noise_alpha: None
• optim_target_modules: None
• batch_eval_metrics: False
• eval_on_start: False
• use_liger_kernel: False
• eval_use_gather_object: False
• average_tokens_across_devices: False
• prompts: None
• batch_sampler: batch_sampler
• multi_dataset_batch_sampler: round_robin

Training Logs

Epoch	Step	cosine_ndcg@10
1.0	22	0.9023
2.0	44	0.9455
2.2727	50	0.9609
3.0	66	0.9609
4.0	88	0.9692
4.5455	100	0.9692
5.0	110	0.9692
6.0	132	0.9692
6.8182	150	0.9692
7.0	154	0.9692
8.0	176	0.9638
9.0	198	0.9692
9.0909	200	0.9692
10.0	220	0.9692

Framework Versions

• Python: 3.11.11
• Sentence Transformers: 3.3.1
• Transformers: 4.48.3
• PyTorch: 2.5.1+cu124
• Accelerate: 1.3.0
• Datasets: 3.3.2
• Tokenizers: 0.21.0

Citation

BibTeX

Sentence Transformers

@inproceedings{reimers-2019-sentence-bert,
    title = "Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks",
    author = "Reimers, Nils and Gurevych, Iryna",
    booktitle = "Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing",
    month = "11",
    year = "2019",
    publisher = "Association for Computational Linguistics",
    url = "https://arxiv.org/abs/1908.10084",
}

MatryoshkaLoss

@misc{kusupati2024matryoshka,
    title={Matryoshka Representation Learning},
    author={Aditya Kusupati and Gantavya Bhatt and Aniket Rege and Matthew Wallingford and Aditya Sinha and Vivek Ramanujan and William Howard-Snyder and Kaifeng Chen and Sham Kakade and Prateek Jain and Ali Farhadi},
    year={2024},
    eprint={2205.13147},
    archivePrefix={arXiv},
    primaryClass={cs.LG}
}

MultipleNegativesRankingLoss

@misc{henderson2017efficient,
    title={Efficient Natural Language Response Suggestion for Smart Reply},
    author={Matthew Henderson and Rami Al-Rfou and Brian Strope and Yun-hsuan Sung and Laszlo Lukacs and Ruiqi Guo and Sanjiv Kumar and Balint Miklos and Ray Kurzweil},
    year={2017},
    eprint={1705.00652},
    archivePrefix={arXiv},
    primaryClass={cs.CL}
}